Home / Intelligence / Briefs / Advances in International Health Technology Assessment Collaboration
How will Joint Clinical Assessment impact patient access to medicines in Europe?
Joint clinical assessment (JCA) has been implemented for new cancer medicines and advanced therapy medicinal products (ATMP) from January 2025 in the European Union (EU). The first panel session at the London 2025 Galien Foundation Forum focused on international health technology assessment (HTA) collaboration and the expected impact of JCA on patient access to medicines in the EU.
The panel included representatives from the European Patients’ Forum, the European Medicines Agency (EMA), the Member State Coordination Group on HTA (HTACG), the National Institute for Health and Care Excellence (NICE), and industry. They discussed the ambitions, challenges, and implications of a harmonized HTA process in Europe.
This advisory brief summarizes the key learnings from that panel.
Complete the form below to access the advisory brief.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
Webinars
Most-Favored Nation Pricing Policy: Why One Size Doesn’t Fit All
September 25, 2025 | 1:00 – 2:00 PM ET
As U.S. leaders promote a drug pricing vision based on Most-Favored Nation (MFN) principles, ensuring that U.S. consumers have access to the best available prices among advanced nations, pharmaceutical companies are facing increased uncertainty and are evaluating strategic options. This session will bring together Trinity experts to discuss how this initiative could realistically lead to […]
Sign Up Now
Blog
A Shrinking Safety Net: OBBBA’s Ripple Effects on the Pharma Industry
President Trump signed the “One Big Beautiful Bill Act” (OBBBA) into law on July 4, 2025. The OBBBA is projected to reduce federal health spending by an estimated $900 billion[1] over the next decade. Central to the legislation is the estimated loss of insurance coverage for 16 million people[2], fundamentally reshaping access to care for […]
Read More
Webinars
Part D in Peril: The Inconvenient Math of IRA Part D Redesign
Available On Demand
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Watch Now